PUT/VERTEX PHARMACEUTICALS/450/0.1/17.01.25 | Real-time BOERSE MUENCHEN 15:25:26 01/07/2024 BST | ||
| 1.82 EUR | -2.67% |
|
| Current month | -38.08% | ||
| 1 month | -36.61% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 01/07/24 | 1.82 | -2.67% |
| 28/06/24 | 1.87 | +2.19% |
| 27/06/24 | 1.83 | -3.68% |
| 26/06/24 | 1.9 | +1.60% |
| 25/06/24 | 1.87 | +1.63% |
Real-time BOERSE MUENCHEN
Last update July 01, 2024 at 03:25 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Goldman Sachs |
| WKN | GQ7FBY |
| ISIN | DE000GQ7FBY5 |
| Date issued | 12/10/2023 |
| Strike | 450 $ |
| Maturity | 17/01/2025 (200 Days) |
| Parity | 10 : 1 |
| Emission price | 8.2 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 10.11 € |
|---|---|
| Lowest since issue | 1.71 € |
| Spread | 0.2 € |
| Spread % | 10.15% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
468.7
USD
Average target price
468.3
USD
Spread / Average Target
-0.10%
- Stock Market
- Warrants
- Warrant
